Geron names Molineaux, Bradbury to its board
MENLO PARK, Calif. (AP) — Drug developer Geron Corp. said Friday it appointed Susan Molineaux and Daniel Bradbury to its board of directors.
Molineaux is the president and CEO of Calithera Biosciences and co-founder and former chief science officer and CEO of Proteolix Inc. Bradbury was the CEO of diabetes drug maker Amylin Pharmaceuticals from March 2007 until August, when Amylin was acquired by Bristol-Myers Squibb Co.
Geron's board now has 10 directors.
Geron said Molineaux was responsible for leading development of Proteolix's cancer drug carfilzomib. Onyx Pharmaceuticals Inc. bought Proteolix in 2009, and in July 2012, the Food and Drug Administration approved carfilzomib as a treatment for multiple myeloma, a bone marrow cancer. The drug is being marketed under the name Kyprolis.
Molineaux was president and CEO of Proteolix from January 2006 to February 2009. Her successor was John Scarlett, who is now the president and CEO of Geron.